Home › Compare › NICXF vs BTI

NICXF vs BTI: Dividend Comparison 2026

NICXF yields 666.67% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NICXF wins by $608115.62M in total portfolio value
10 years
NICXF
NICXF
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full NICXF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — NICXF vs BTI

📍 NICXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNICXFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NICXF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NICXF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NICXF
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, NICXF beats the other by $399,126,863,625.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NICXF + BTI for your $10,000?

NICXF: 50%BTI: 50%
100% BTI50/50100% NICXF
Portfolio after 10yr
$304057.85M
Annual income
$234,780,510,801.44/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

NICXF
No analyst data
Altman Z
-14.8
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NICXF buys
0
BTI buys
0
No recent congressional trades found for NICXF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNICXFBTI
Forward yield666.67% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$608115.66M ✓$37.7K
Annual income after 10y$469,561,018,816.25 ✓$2,786.64
Total dividends collected$596792.85M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NICXF vs BTI ($10,000, DRIP)

YearNICXF PortfolioNICXF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$77,367$66,666.67$11,299$598.92+$66.1K → NICXF
2$564,818$482,035.31$12,794$703.91+$552.0K → NICXF
3$3,893,246$3,288,890.67$14,518$829.07+$3.88M → NICXF
4$25,352,760$21,186,987.16$16,513$978.64+$25.34M → NICXF
5$156,070,781$128,943,327.59$18,827$1,157.84+$156.05M → NICXF
6$908,837,800$741,842,064.29$21,518$1,373.12+$908.82M → NICXF
7$5,009,769,782$4,037,313,336.56$24,657$1,632.46+$5009.75M → NICXF
8$26,159,339,258$20,798,885,591.56$28,329$1,945.74+$26159.31M → NICXF
9$129,490,317,125$101,499,824,118.87$32,637$2,325.33+$129490.28M → NICXF
10$608,115,658,140$469,561,018,816.25$37,708$2,786.64+$608115.62M → NICXF

NICXF vs BTI: Complete Analysis 2026

NICXF — Stock

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Full NICXF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this NICXF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NICXF vs SCHDNICXF vs JEPINICXF vs ONICXF vs KONICXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.